Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.

Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the “Insiders Fund”. A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500’s -0.95%, 15.2%, and 9.98% […]

Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a positive market response. Management credited execution in specialty pharmaceuticals, especially through its Management Services Organizations (MSOs) like OneOncology and RCA, as a core driver of growth, while digital transformation initiatives improved operational efficiency. CEO Robert Mauch highlighted the company’s unique positioning in

The Morning Bull - US Market Morning Update Thursday, Aug, 13 2026 US stock futures are pointing slightly higher this morning, with E-mini S&P 500 contracts up about 0.2% and Nasdaq-100 futures ahead by roughly 0.6%, as investors focus on a key inflation update and what it could mean for interest rates. July CPI is expected at 3.4% year on year, with core inflation seen at 2.5%, which would suggest the cost of living is still rising but closer to the central bank’s comfort zone. At the same...

US equity indexes ended mixed Wednesday amid stock gains by some major technology stocks and a four-

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t

Revenue hit $84.8 billion as GLP-1 sales surged 25% despite manufacturer price headwinds.

Cencora has underperformed the broader market over the past year, yet analysts remain highly bullish about the stock’s prospects.

AbbVie commands a premium valuation for its specialty drug pipeline, while CVS Health trades at a discount despite managing 37 million medical members.

S&P 500 drug distributor Cardinal Health easily topped fiscal fourth-quarter earnings forecasts despite a revenue shortfall. Rival McKesson, which whipsawed after its earnings report last week, has climbed back near a buy point. Cencora, another big S&P 500 drug distributor, also is near a buy point, but MCK stock may be the strongest of the three.

AbbVie generates stronger free cash flow and trades at a lower forward multiple, while Abbott offers diversification and a healthier balance sheet.

Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.

Cencora (NYSE:COR) reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook. Adjusted operating

Moby summary of Cencora, Inc.'s Q3 2026 earnings call

Cencora Inc (COR) delivered 17% adjusted operating income growth and raised its full-year EPS outlook, driven by robust specialty performance and strategic share repurchases.

Cencora (NYSE:COR) has amended its credit and receivables facilities, including changes to its multi currency revolving credit facility and receivables securitization arrangements. The company has adjusted the size and maturity profile of its revolving credit facility and updated terms related to its receivables securitization structure. These financing changes are recent and represent material developments for Cencora’s capital structure and liquidity toolkit. Cencora operates as a major...

Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.

Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Cencora (NYSE:COR) reported third-quarter results that exceeded Wall Street expectations, prompting the pharmaceutical services company to raise its full-year earnings guidance. The stronger performance helped lift the shares more than 3% in pre-market trading.

Cencora (COR) delivered earnings and revenue surprises of +2.52% and -0.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $84.75 billion. Its non-GAAP profit of $4.48 per share was 3% above analysts’ consensus estimates.

McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.

XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.

COR's Q3 results could reflect specialty pharma strength, oncology expansion and margin gains, even as pricing dynamics and GLP-1 trends pressure revenues.

McKesson heads into Q1 with AI-driven efficiency, specialty momentum and oncology growth in focus as pricing dynamics may temper revenues.

SOLV's Q2 results are likely to benefit from segment strength, Acera gains and cost savings, offset by tariffs and ERP-related sales timing shifts.

Globus Medical will report Q2 results on Aug. 6. Investors will be keen to know whether Enabling Technologies and Spine strength aid revenue & earnings growth.

Carillon Tower Advisers, an investment management company, released its second-quarter 2026 investor letter for the “Carillon Eagle Mid Cap Growth Fund”. A copy of the letter is available to download here. Mid-cap stocks delivered strong results, with the Russell Midcap® Growth Index rising 14.55% and slightly outperforming the Russell Midcap® Value Index’s 13.40% gain. Information […]

Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

Alignment Healthcare (ALHC) delivered earnings and revenue surprises of +30.77% and +1.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

CRL is set to report Q2 results on Aug. 5 as investors watch segment demand, divestitures, and whether the company can extend its earnings beat streak.

RVTY heads into Q2 earnings with improving Life Sciences demand and resilient Diagnostics. Can stronger margins offset lingering headwinds?

Concentra (CON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ZBH heads into Q2 earnings with expectations of modest revenue growth as investors watch demand trends across knees, hips and robotics.

BrightSpring heads into Q2 earnings with pharmacy and provider momentum, rising estimates and margin gains despite IRA and generic-conversion pressure.

HSIC heads into Q2 earnings with expectations for revenue and EPS growth as dental, specialty products and AI-enabled technology remain in focus.

A steadily shrinking share count and a giant float owed to suppliers are handing owners a bigger slice of the drug distributor each year, even as drug-pricing worries hang over the stock.

Recent screening for stocks with rising P/E ratios and consistent price gains relative to the S&P 500 has put Cencora (COR) in focus for investors tracking valuation and earnings expectations. See our latest analysis for Cencora. Cencora’s recent screening attention comes after a generally mixed year for the share price, with a 30 day share price return of 8.94% contrasting with a year to date decline of 8.55% and a 1 year total shareholder return of 7.53%. This suggests longer term holders...

Cencora stock has delivered a strong 167.1% return over the past 5 years, yet its current valuation still screens as cheap. An intrinsic value estimate from a Discounted Cash Flow (DCF) model suggests the shares trade at a meaningful discount to that estimate, while market multiples also lean toward an undervalued verdict. A 167.1% total return over 5 years sets a high bar for Cencora. Any hint that cash flow growth slows or that returns on capital plateau may make the current valuation...

HCA tops Q2 EPS estimates on higher admissions and revenue per admission but trims parts of its 2026 guidance as higher expenses and weaker surgical volumes weigh on results.

COR's specialty expansion, supply-chain investments and international momentum support growth, though pricing, debt and regulation pose risks.

AIM, HAS, FOX, COR and ISRG make the list of stocks with rising P/E ratios, a screen highlighting companies investors may view as having stronger earnings potential.

Molina beats Q2 earnings estimates as lower operating expenses offset weaker premium revenues, declining membership and softer investment income, while the company raises its 2026 earnings guidance.

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Cencora is scheduled to release its third-quarter results next month, with analysts projecting single-digit earnings growth.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Cencora (NYSE:COR) and its peers.